Literature DB >> 9883743

C-type natriuretic peptide: the endothelial component of the natriuretic peptide system.

H H Chen1, J C Burnett.   

Abstract

C-type natriuretic peptide (CNP) is a 22-amino-acid peptide, structurally related to but genetically distinct from atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP). Whereas ANP and BNP are ligands for a guanylyl cyclase-coupled receptor, the NPR-A receptor, CNP is a specific ligand for the NPR-B receptor. In addition to clearance by the NPR-C receptor, CNP is subject to degradation by the ectoenzyme neutral endopeptidase 24.11 (NEP), which is widely distributed in the kidney, lung, heart, and endothelial cells. Although initially identified in porcine brain, CNP immunoreactivity has been found in human vascular endothelial cells, plasma, and kidney. CNP has potent systemic cardiovascular actions, which include reductions in cardiac filling pressures and output, secondary to vasorelaxation and decreases in venous return, but has minimal renal actions. Unlike ANP, CNP is a selective endothelium-independent venodilator. However, it is also a potent coronary vasodilator. Expression of the CNP gene by the endothelial cells, the presence of CNP receptors on vascular smooth muscle cells (VSMCs), and the antimitogenic effect of CNP on VSMCs suggest that CNP is produced by the endothelium and acts on adjacent VSMCs serving as an autocrine/paracrine endothelium-derived vasoregulatory system.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9883743

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  32 in total

Review 1.  Vasopeptidase inhibition: a new direction in cardiovascular treatment.

Authors:  J R Asher; A J Naftilan
Journal:  Curr Hypertens Rep       Date:  2000-08       Impact factor: 5.369

2.  Effect of sialylated O-glycans in pro-brain natriuretic peptide stability.

Authors:  Jingjing Jiang; Nicole Pristera; Wei Wang; Xiumei Zhang; Qingyu Wu
Journal:  Clin Chem       Date:  2010-03-26       Impact factor: 8.327

Review 3.  Novel Biomarkers for the Risk Stratification of Heart Failure with Preserved Ejection Fraction.

Authors:  Jeremy Cypen; Tariq Ahmad; Jeffrey M Testani; Adam D DeVore
Journal:  Curr Heart Fail Rep       Date:  2017-10

4.  The role of endothelium and endogenous vasoactive substances in sepsis.

Authors:  G Kotsovolis; K Kallaras
Journal:  Hippokratia       Date:  2010-04       Impact factor: 0.471

Review 5.  Natriuretic Peptides as a Novel Target in Resistant Hypertension.

Authors:  Pratik Patel; Horng H Chen
Journal:  Curr Hypertens Rep       Date:  2015-03       Impact factor: 5.369

6.  C-type natriuretic peptide inhibits leukocyte recruitment and platelet-leukocyte interactions via suppression of P-selectin expression.

Authors:  Ramona S Scotland; Marc Cohen; Paul Foster; Matthew Lovell; Anthony Mathur; Amrita Ahluwalia; Adrian J Hobbs
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-22       Impact factor: 11.205

7.  Effects of C-type natriuretic peptide on rat cardiac contractility.

Authors:  J M Brusq; E Mayoux; L Guigui; J Kirilovsky
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

Review 8.  Central role of guanylyl cyclase in natriuretic peptide signaling in hypertension and metabolic syndrome.

Authors:  G Martel; P Hamet; Johanne Tremblay
Journal:  Mol Cell Biochem       Date:  2009-11-25       Impact factor: 3.396

9.  Alterations in the natriuretic hormone system related to cardiopulmonary bypass in infants with congestive heart failure.

Authors:  J M Costello; C L Backer; P A Checchia; C Mavroudis; R G Seipelt; D M Goodman
Journal:  Pediatr Cardiol       Date:  2004 Jul-Aug       Impact factor: 1.655

10.  Vascular natriuretic peptide receptor-linked particulate guanylate cyclases are modulated by nitric oxide-cyclic GMP signalling.

Authors:  Melanie Madhani; Ramona S Scotland; Raymond J MacAllister; Adrian J Hobbs
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.